BluePrint® 80-Gene Molecular Subtyping Assay

Deeper insight into tumor pathways, leading to more clinically actionable biology

The prevalence of molecular subtyping in breast cancer has been increasing as the development of novel diagnostic tools to interrogate tumor biology has evolved.  Traditional subtyping (such as IHC or FISH) assess a tumor by looking at cell surface characteristics, while molecular subtyping looks deeper at the functional level to see which genes are driving the tumor’s behavior.  BluePrint functional molecular subtyping classifies breast cancer into three distinct subtypes: Luminal-type, HER2-type and Basal-type, each with marked differences in long-term outcome and response to neoadjuvant chemotherapy.10